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Prognostic Evaluation of Patients With Multicentric
Papillary Thyroid Microcarcinoma
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Jen-Der Lin3*
Background/Purpose: Patients with papillary thyroid microcarcinoma (PTMC) often have an excellent
prognosis. We hypothesize that patients with multicentric PTMC are associated with good clinical out-
come, although multicentricity in papillary thyroid carcinoma may be associated with poor prognosis.
Methods: Retrospective analysis of multicentric PTMC cases in one medical center enrolled from 1987 to
2008 was conducted. At the end of follow-up, patients were classified as “recurrence-free” or “recurrence
or persistent disease”. The tumor–node–metastasis (TNM) staging system was used, and (T1, N0, M0) was
regarded as “early clinical stage”, whereas (T3–4, any N, any M) or (any T, N1, or M1) was regarded as 
“advanced clinical stage”.
Results: There were 61 patients with a median age of 45 years. After a median follow-up period of 7.3 years
(range: 2.1–22.1 years), the overall cause-specific survival rate was 98.36%. The patients with tumor diam-
eters < 0.5 cm were all recurrence-free. Advanced clinical stage, especially distant metastasis, was highly 
associated with recurrence or persistent disease.
Conclusion: Our results demonstrate excellent prognosis in multicentric PTMC patients. No patients with
tumor diameter < 0.5 cm had recurrence or persistent disease. Tumor size is an important risk factor in 
patients with multicentric PTMC.
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Although multicentricity is not a classical risk
factor of papillary thyroid carcinoma (PTC),1–3
multicentricity is frequently associated with an
increased risk of recurrence, distant metastasis and
mortality in PTC patients.4–7 To date, there are no
reports specifically on the clinical features and
prognosis in patients with multicentric papillary
thyroid microcarcinoma (PTMC). Accordingly,
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we retrospectively evaluated 61 patients with mul-
ticentric PTMC from 325 PTMC patients treated at
Chang Gung Medical Center in Taiwan, to show
their clinical manifestations and prognosis.8
Patients and Methods
Patients
Between January 1987 and December 2008, 325
patients were diagnosed with PTMC and received
follow-up treatment for > 2 years after surgery 
at Chang Gung Medical Center, Taiwan. Among
these, 61 had multicentric PTMC based on the
final histopathological analyses of 325 PTMC
patients. Multicentric PTMC was defined as the
occurrence of at least two papillary cancer lesions
in the thyroid, either within one lobe or in both.
The diameter of each lesion was ≤ 1.0 cm based
on the final pathologic records.
Initial survey and primary therapy
Most of the 61 patients underwent preoperative
thyroid ultrasonography and fine needle aspi-
ration cytology (FNAC) due to palpable thyroid
nodules. All 61 patients received surgery, and frozen
sections were obtained from most of them during
surgery. In this paper, the term total thyroidectomy
refers to near total or total thyroidectomy with or
without central compartment and selective bilat-
eral neck lymph node dissection; non-total thy-
roidectomy refers to subtotal thyroidectomy or
lobectomy.
Follow-up
After surgery, most patients received long-term
thyroid hormone suppressive therapy. Postop-
erative investigation usually consisted of thyroid
ultrasonography, 74–185 MBq (2–5 mCi) radioac-
tive 131I whole-body diagnostic scanning, serum-
stimulated thyroglobulin (Tg), anti-Tg antibody
test, and thyroid function. Postoperative investi-
gation was performed 1 month after surgery and
at 6–12-month intervals thereafter. Serum Tg lev-
els were measured with an immunoradiometric
assay kit (CIS Bio International, Gif-sur-Yvette,
France). Large-dose 131I therapy was performed
when recurrent lesions were suspected. Surgery
was performed whenever recurrent localized le-
sions were confirmed based on thyroid ultrasonog-
raphy with FNAC.
Outcome assessment
At the end of follow-up, patients were classified as
“recurrence-free” or “recurrence or persistent dis-
ease” based on the treatment outcome. Recurrence-
free was defined as absence of distant metastasis
and no local recurrence based on physical and
noninvasive imaging (e.g. thyroid ultrasonogra-
phy, chest X-ray, 131I scan, computed tomography,
magnetic resonance imaging, and positron emis-
sion tomography) at clinical follow-up. Recurrence
was defined as distant metastasis or local tumor
recurrence during clinical follow-up, and persis-
tent disease as distant metastasis at diagnosis
and throughout follow-up.
Tumor staging and risk stratification
Tumors were staged according to the International
Union against Cancer (UICC) tumor–node–
metastasis (TNM) criteria (6th edition).3 In this
study, patients with confined intrathyroid PTMC
(T1, N0, M0) were regarded as “early clinical stage”,
and extra-thyroid extension PTMC (T3–4, any N,
any M) or those with lymph node metastasis, soft
tissue involvement, or distant metastasis (any T,
N1, or M1) were regarded as “advanced clinical
stage”.
Statistical analysis
Metric data were presented as median and range,
and were analyzed by Mann–Whitney test. The
χ2 or Fisher’s exact test was used for categorical
data. The association between tumor size and 
recurrence or persistent disease was explored by
a receiver-operating-characteristic (ROC) curve.
Besides, tumor size was dichotomized based on
the best cut-off level chosen by ROC curve and
the Yuden Index. Recurrence-free survival was an-
alyzed by the Cox proportional-hazards model.
Multivariate logistic regression was used to exam-
ine factors associated with recurrence or persistent
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disease of multicentric PTMC. Potential con-
founders, collinearity and interaction between fac-
tors were evaluated for building the final model.
Statistical significance was set at a two-sided p
value of ≤ 0.05. All analyses were conducted with
the use of statistical software (Stata, version 10.1;
StataCorp, College Station, TX, USA).
Results
Clinical presentations
Based on the final histopathology from 325 PTMC
patients, there were 61 multicentric and 264 uni-
focal PTMC patients. Of the 61 multicentric PTMC
patients, there were 46 women and 15 men with
a median age of 45 years (range: 18–72 years).
After a median follow-up period of 7.3 years
(range: 2.1–21.1 years), one of the 61 patients
died of metastatic thyroid cancer 5.33 years after
diagnosis. Twenty-seven patients presented with
asymptomatic thyroid nodules and underwent
surgery because malignancy or suspected malig-
nancy was detected by thyroid ultrasonography
and FNAC; 21 patients underwent surgery due 
to the presence of a large goiter; nine patients
underwent surgery as a result of hyperthyroidism;
and four patients underwent thyroid surgery be-
cause metastatic lesions were suspected to origi-
nate from the thyroid gland. Table 1 shows a
comparison of the clinical characteristics between
multicentric (n= 61) and unifocal (n= 264) PTMC
patients.
Forty of the 61 multicentric PTMC patients
presented with tumor in both lobes (65.6%),
whereas the other 21 patients had PTMC con-
fined to only one lobe (34.4%). Accordingly, mul-
ticentricity was observed in 61 of 325 PTMC
patients (18.8%), and the involvement of both
lobes was detected in 40 of 325 PTMC patients
(12.3%). Of the 61 multicentric PTMC patients,
50 underwent preoperative thyroid ultrasonogra-
phy and FNAC, and PTC was detected in 17 of
these (34%); 49 were examined by frozen sec-
tions during surgery, and PTC was detected in 43
of 49 patients (87.8%). Sixteen of 61 patients were
diagnosed with PTC incidentally based on final
pathology (26.2%).
Table 1. Comparison of the clinical characteristics of multicentric and unifocal papillary thyroid
microcarcinoma patientsa
Multicentric (n = 61) Unifocal (n = 264) p
Sex, female 46 (75.4) 229 (86.7) 0.027
Age (yr) 45 (18–72) 41 (15–80) 0.148
Follow-up period (yr) 7.3 (2.1–21.1) 8.9 (2.0–24.3) 0.036
Hyperthyroidism 9 (14.8) 74 (28.0) 0.032
Identified by FNAC 17 (34.0) (n = 50) 49 (23.7) (n = 207) 0.134
Diagnosed by frozen sections 43 (87.8) (n = 49) 125 (70.2) (n = 178) 0.013
Diagnosed incidentally by final 16 (26.2) 133 (50.4) 0.001
pathology (incidental finding)
Tumor size (cm) 0.7 (0.2–1.0) 0.5 (0.1–1.0) 0.059
Tumor size ≥ 0.7 cm 34 (55.7) 100 (37.9) 0.011
Postoperative 131I accumulated 75 (0–1,050) 30 (0–1,035) < 0.001
dose (mCi)
Total thyroidectomy 52 (85.3) 132 (50.0) < 0.001
1 mo postoperative Tgb (ng/mL) 6.9 (0–31,993) (n = 50) 3.0 (0–249) (n = 125) 0.030
Postsurgical relapsec 10 (16.4) 9 (3.4) 0.001
Disease specific mortality 1 (1.6) 1 (0.4) 0.341
aData are presented as n (%) for categorical variables and median (range) for continuous variables; bPost total-thyroidectomy stimulated
thyroglobulin; cincluding cases with recurrence or persistent disease. FNAC = fine needle aspiration cytology; Tg = thyroglobulin.
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Outcome and prognosis
Fifty-two of the 61 multicentric PTMC patients
received total thyroidectomy (85.2%), including
nine that underwent secondary operation for
complete thyroidectomy; the other nine patients
underwent non-total thyroidectomy (14.8%), in-
cluding seven undergoing subtotal thyroidectomy
and two undergoing lobectomy. The diameter of
each thyroid lesion in the 61 patients was ≤1.0 cm.
Fifty-three of the 61 patients (86.9%) were ad-
ministered at least 1.1 GBq (30 mCi) 131I during
postoperative follow-up. Two patients had per-
manent hypoparathyroidism after total thyroi-
dectomy; however, there were no other serious
complications related to surgery and 131I therapy.
Of the 61 multicentric PTMC patients, 51
(83.6%) were recurrence-free and 10 (16.4%) had
recurrence or persistent disease at clinical follow-
up, including six with recurrence and four with
persistent disease. Table 2 shows a comparison
of the clinical characteristics of 51 recurrence-free
and 10 recurrence or persistent disease patients.
The data shows that larger tumor diameter, higher
postoperative serum stimulated Tg level and ad-
vanced clinical stage were associated with recur-
rence or persistent disease. The area under the
ROC curve of tumor size predicting recurrence 
or persistent disease was 0.72 (95% confidence
interval: 0.58–0.87). There was no recurrence or
persistent disease for tumor diameter < 0.5 cm
(sensitivity 100%, specificity 35.3%), and the best
cut-off level was 0.7 cm (sensitivity 90.0%, speci-
ficity 51.0%). Patients with tumor size < 0.7 cm
were designated as the small tumor group and the
remainder as the large tumor group. The Figure
shows the Kaplan–Meier recurrence-free survival
curves between patients with different tumor size
and clinical stages (excluding 4 patients with per-
sistent disease). Patients with advanced clinical
stage and large tumor size had higher recurrent rate.
Table 3, which summarizes the results of the
multivariate logistic regression, reveals the factors
Table 2. Comparison of the clinical data of recurrence-free and recurrence or persistent disease multicentric
papillary thyroid microcarcinoma patientsa
Recurrence-free Recurrence or persistent 
(n = 51) disease (n = 10)
p
Sex, female 42 (82) 4 (40) 0.010
Age (yr) 45 (18–72) 48 (24–72) 0.489
Follow-up period (yr) 7.3 (2.3–21.1) 8.1 (2.1–13.2) 0.907
Both lobes involved 34 (67) 6 (60) 0.725
Hyperthyroidism 7 (14) 2 (20) 0.633
TNM stage < 0.001
T1, N0, M0 41 (80) 2 (20)
T3–4, N0, M0 1 (2) 0
T1, N1, M0 6 (12) 3 (30)
T3–4, N1, M0 3 (6) 1 (10)
T1, N0, M1 0 3 (30)
T3–4, N1, M1 0 1 (10)
Advanced clinical stage 10 (20) 8 (80) < 0.001
Tumor size (cm) 0.6 (0.2–1.0) 0.95 (0.5–1.0) 0.025
Tumor size ≥ 0.7 cm 25 (49) 9 (90) 0.033
Postoperative 131I accumulated dose (mCi) 60 (0–445) 435 (90–1,050) < 0.001
Total thyroidectomy 42 (82) 10 (100) 0.332
1 mo postoperative Tgb (ng/mL) 4.95 (0–35.4) (n = 40) 186.1(3.05–31993) (n = 10) 0.000
aData are presented as n (%) for categorical variables and medians (ranges) for continuous variables; bPost-total thyroidectomy stim-
ulated thyroglobulin. Advanced clinical stage: (T3–4, any N, any M) or (any T, N1, or M1). TNM = tumor–node–metastasis.
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associated with recurrence or persistent disease.
The results indicated that advanced clinical stage
and large tumor size were significantly and inde-
pendently associated with recurrence or persistent
disease of multicentric PTMC.
Discussion
Although PTMC patients usually have an excellent
prognosis,9–13 the clinical behavior and prognosis
of multicentric PTMC patients is not well known.
This study revealed an excellent cause-specific sur-
vival rate of 98.4% for multicentric PTMC patients
after a median follow-up period of 7.3 years.
Based on the results of this study, patients with
multicentric PTMC have larger tumor diameter and
higher rate of recurrence or persistent disease than
those with unifocal PTMC, although their prog-
nosis is excellent. The frequency of multicentric-
ity in PTMC is reported to be 15–32%.10–12,14,15
Both thyroid lobes are involved in 10–19% of
PTMC patients.11,12 Our results are similar to pre-
vious studies, in which multicentricity was ob-
served in 18.8% of patients, and both lobes were
involved in 12.3% of cases. Neck ultrasonogra-
phy is a sensitive and cost-effective method for
the detection of thyroid cancer, and it increases
the frequency of preoperative diagnosis of thyroid
microcarcinomas.16–19 Both ultrasonography with
FNAC and frozen sections during surgery are
helpful in identifying multicentricity of thyroid
cancer in PTMC patients, which might avoid sec-
ondary operation for these patients, although the
diagnostic rate of FNAC is low (23.7–34%) for
PTMC patients, because it is not easy to perform
a successful FNAC on thyroid microcarcinoma.
Although there have been no reports specif-
ically on the prognostic factors in patients with
multicentric PTMC, previous studies on PTMC
patients have indicated that tumor size, postop-
erative Tg level, presence of lymph node metas-
tases at diagnosis, sex, and extent of surgery are
prognostic factors.10,12,14,15,20,21 Based on the ROC
curve in the present study, multicentric PTMC
patients with tumor diameter < 0.5 cm tended to
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Kaplan–Meier recurrence-free survival curve
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Figure. Kaplan–Meier recurrence-free survival curves between patients with different tumor size and clinical stages.
Solid line: early clinical stage and small tumor size; dotted line: advanced clinical stage and small tumor size; long dashed
line: early clinical stage and large tumor size; short dashed line: advanced clinical stage and large tumor size.
Table 3. Factors predicting recurrence or
persistent disease in patients with
multicentric papillary thyroid carcinoma
Variables OR (95% CI)a p
Clinical stage 45.2 (5.1–397.2) 0.001
(early vs. advanced)
Tumor size 234.5 (3.5–15530.6) 0.011
aLogistic regression. Early clinical stage: (T1, N0, M0); advanced
clinical stage: (T3–4, any N, any M) or (any T, N1, or M1).
OR = odds ratio; CI = confidence interval.
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be recurrence-free. From the results of multivari-
ate logistic regression, advanced clinical stage and
larger tumor size were independently associated
with recurrence or persistent disease. Tumor size
was a more important risk factor than clinical stage
in the present study. As the tumor size increased,
the prognosis became poorer. Additionally, ad-
vanced clinical stage in the present study included
lymph node metastasis. Although lymph node
metastasis increased risks of tumor recurrence, it
did not influence survival rate in previous stud-
ies.22,23 Four patients had persistent disease in the
present study, and all of them underwent thyroid
surgery because metastatic lesions originated from
the thyroid; these patients actually had the poor-
est clinical outcome, and one of them died of
metastatic thyroid cancer.
Whether multicentric tumors originate from
different unrelated clones or from one focus with
intrathyroid spreading is unclear. Results from
studies such as those involving polymerase chain
reactions with the human androgen receptor gene
or BRAF gene imply that noncontiguous tumor
foci originate from independent precursors,24,25
whereas another study has shown that multicentric
papillary lesions arise from the same clone.26 To
date, it is unknown whether the clinical presen-
tations and prognosis differ between these two
disease subgroups in multicentric PTC or PTMC
patients.
There were some limitations in this retrospec-
tive study. Because 14.8% of multicentric PTMC
cases had non-total thyroidectomy, it might have
been difficult to identify recurrence by serum Tg
levels and 131I scans. We determined recurrence
based mainly on physical and imaging studies
(e.g. thyroid ultrasonography, chest X-ray, 131I scan,
computed tomography, magnetic resonance im-
aging, and positron emission tomography) other
than serum Tg levels, and thus recurrence might
have been under-reported as a result.
In conclusion, multicentric PTMC patients
might have an excellent prognosis. Patients with
tumor diameter < 0.5 cm tend to be recurrence-
free. Tumor size is an important independent
prognostic factor in multicentric PTMC patients.
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